Poly-chemotherapy plus rituximab followed by autologous stem cell transplantation (auto-SCT) is standard care for untreated young patients with mantle cell lymphoma (MCL). Despite this intensive treatment, transplant patients remain highly susceptible to relapse over time. The French SFGM-TC performed a national survey on reduced-intensity conditioning allogeneic stem cell transplantation (RIC-allo-SCT) for fit relapsed/refractory patients who failed after auto-SCT (n = 106). Median times of relapse after auto-SCT, and from auto-SCT to RIC-allo-SCT were 28 months and 3.6 years, respectively. Sixty per cent of patients received at least three lines of treatment before RIC-allo-SCT. Conditioning regimens for RIC-allo-SCT were heterogeneous. Twenty patients experienced grade III/IV aGvHD, extensive cGvHD was reported in 28 cases. Median follow-up after RIC-allo-SCT was 45 months. Median PFS after RIC-allo-SCT was 30.1 months and median overall survival was 62 months. Treatment-related mortality (TRM) at 1 year and 3 years were estimated at 28% and 32%, respectively. A total of 52 patients died; major causes of death were related to toxicity (n = 34) and MCL (n = 11). Patients in good response before RIC-allo-SCT experienced a better PFS and OS. Our work highlights the need for new RIC-allo-SCT MCL-tailored approaches to reduce TRM, and early and late relapse.
INTRODUCTION
First-line treatment of mantle cell lymphoma (MCL) is adapted to age and comorbidities. 1 The ESMO conference consensus recommends treating young and fit patients (nearly half of all patients) with an immuno-chemotherapy induction including high-dose aracytine followed by autologous stem cell transplantation (auto-SCT). 2 CR after auto-SCT was successful in 80% of cases, but all patients, including good responders, remain highly susceptible to relapse over time. The recent EBMT study shows that median overall survival (OS) of patients who relapsed after auto-SCT is 19 months. 3 For relapse or refractory patients with chemo-resistant disease, allogeneic stem cell transplantation (allo-SCT) appears to be a curative treatment given the graft versus MCL effect (GV-MCL). 4, 5 Given the median age at diagnosis is 65-70y, 6 reduced-intensity conditioning regimens (RIC-allo-SCT) are the main options for patients who fail after auto-SCT. Therefore, the outcome of patients who previously received auto-SCT, relapsed and then underwent RIC-allo-SCT rescue is an important topic in clinical practice. Published data regarding allo-SCT in MCL remain sparse, with discrepancies between studies regarding median progression-free survival (PFS), OS and treatment-related mortality (TRM). [7] [8] [9] [10] [11] Studies on allo-SCT in MCL include heterogeneous groups of patients treated or untreated with rituximab. Many patients did not undergo auto-SCT before allo-SCT and conditioning regimens were not always RIC. Therefore, the Société Française de greffe de moelle et de thérapie cellulaire group (SFGM-TC) performed a database retrospective study, restricted to MCL patients who relapsed after auto-SCT, addressing the topic of RIC-allo-SCT rescue.
MATERIALS AND METHODS

Study design, patient selection and response assessment
All patients with MCL reported in the SFGM-TC registry, relapsed after auto-SCT and then underwent RIC-allo-SCT were eligible for the present study. Patients who received a tandem auto-SCT followed by RIC-allo-SCT (defined by a delay between auto-SCT and RIC-allo-SCT inferior to 3 months) were excluded. Patients with MCL were defined according to standard criteria at time of diagnosis made by local pathologists. No central review has been performed for the purpose of this study.
In all, 24 French centers participated in the study (Nantes University Hospital, n = 14; Montpellier University Hospital, n = 14; Paoli Calmette Institute, n = 9; Clermont-Ferrand University Hospital, n = 8; Lille University Hospital, n = 8, Poitiers University Hospital, n = 7; Bordeaux University Hospital, n = 7; Pitié-Salpétrière Hospital, n = 6; Grenoble University Hospital, n = 5, Angers University Hospital, n = 5; Brest University Hospital, n = 4; St Antoine Hospital, n = 3; Rouen Becquerel Institute, n = 3; St Louis Hospital, n = 2; St Etienne Cancer Inst., n = 2; Necker Hospital, n = 2; Besançon University Hospital, n = 1; Lyon University Hospital, n = 1; Limoges University Hospital, n = 1; Rennes University Hospital, n = 1; Toulouse University Hospital, n = 1 and Caen University Hospital, n = 1). Referring local physicians were asked to confirm the diagnosis, clinical history and initial presentation, biological characteristics, histological subtypes, number and nature of the treatment lines, disease status at the time of allo-SCT, all data on the allo-SCT procedure and outcome including GvHD grade, and to update follow-up (FU). The International Prognostic index (IPI) and Mantle-cell International Prognostic Index (MIPI) were calculated whenever possible. 12 CR was defined as the disappearance of clinical, radiological and biological disorders related to MCL. PR was defined as a 450% morphological response. Progressive disease (PD) was defined as an increase of 25% in tumor burden. Other responses were defined as stable disease. Clinical outcome analyses were OS, PFS and TRM.
Statistical methods
PFS was calculated from diagnosis to the first event defined as relapse, progression or death from any cause. OS was calculated from diagnosis or RIC-allo-SCT to death. Probabilities of OS and PFS were estimated by the Kaplan-Meier method and compared by a log-rank test and Cox regression. Significance was set at the level of 5%. Analysis of nonrelapse mortality was evaluated with competing risk analysis, relapse being the competing event. Statistical analyses were carried out using R Software version 3.2R Development Core Team (2015). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
RESULTS
Patient characteristics and treatment prior to RIC-allo-SCT A total of, 108 patients met the inclusion criteria. After review, two patients were excluded because of a tandem procedure, thus, 106 patients were included for the final analysis. All RIC-allo-SCT were performed between September 1999 and June 2013, including 80% performed after 2005.
Main characteristics at diagnosis are presented in Table 1 . The median age at diagnosis was 54 years (range, 31-65). Most patients presented with high disease burden (stage III/IV in 98% of cases, missing data in 11 patients). Blastoid variant was present in 14% of patients (data available for 75 patients). Simplified MIPI was high in 16%. Exposure to Rituximab prior RIC-allo-SCT was found in 90% of cases. All patients, except two, received Rituximab before or after RIC-allo-SCT. Auto-SCT was performed in first-line in 72% of cases (100 patients with data available for time of auto-SCT). Auto-SCT conditioning was TBI-based in 37 cases (40%; Cyclophosphamide in 46% and Melphalan in 54%), BEAM in 48 cases (56%). Before RIC-allo-SCT, patients were exposed to an anthracycline-based chemotherapy regimen in 53%; Aracytinebased chemotherapy regimen in 41%.
Median times from auto-SCT to first relapse, and to RIC-allo-SCT were 28 months (range, 3.3-77) and 43 months (range, 4.6-122), respectively. Median number of lines of treatment before RIC-allo-SCT was 2 (range, 2-7) and patients received a median of one line of treatment (range, 1-6) between auto-SCT and RIC-allo-SCT.
Disease status at time of transplantation and conditioning regimens Data are presented in Table 1 . At the time of RIC-allo-SCT, 80% of patients (n = 80) presented with a chemo-sensitive disease (defined as at least PR). Median age at RIC-allo-SCT was 60 years (range, 39-68), peripheral blood was used in 86% of cases. Donor was identical sibling in 34% (n = 36). Non-sibling donors were 10/10 HLA-matched in 48 cases. Prevention of GvHD was heterogeneous but ciclosporin+mycophenolate mofetil were used in almost half of patients (48%). Conditioning regimens were also heterogeneous and incorporated anti-thymoglobulin (ATG) in 60% Abbreviations: ATG = anti-thymoglobulin; auto-SCT = autologous stem cell transplantation; BEAM = BCNU, etoposide, aracytine, melphalan; BU = busulfan; CsA = ciclosporin; Flu = fludarabine; MMF = mycophenolate mofetil; MTX = methotrexate; NA = not asserted; Ric-allo-SCT = reducedintensity conditioning allogeneic SCT.
RIC-allo-SCT in MCL after auto-SCT failure B Tessoulin et al (n = 63). Many drug doses are missing, but most of the patients with busulfan received IV, at 6.4 mg/kg. In all, 50% of patients received fludarabine-busulfan and ATG. TBI (2 Gy) was part of the conditioning regimen in 25% of cases.
Outcomes, PFS and OS Data are presented in Table 2 . Median FU after RIC-allo-SCT was 45 months (range, 3-149) for surviving patients. During RIC-allo-SCT, 57 patients (54%) developed acute GvHD (aGvHD) including 20 patients with grade III/IV. Sixty-five per cent of patients experienced an infectious complication; 11% of the patients developed septic shock. After RIC-allo-SCT, 84 (86%) patients reached CR (including 74% of patients in PR or CR before RIC-allo-SCT), 11 patients reached PR (11%) and 3 (3%) were in PD. Among patients alive at day +100 (n = 95), 59% (n = 48, missing data for 13 patients) developed chronic GvHD (cGvHD) including 26 patients who experienced extensive cGvHD. Fifty-three patients died after RIC-allo-SCT. Major causes of death were RIC-allo-SCT related (n = 34, 67%), relapse and/or progression of the MCL (n = 12; 23%), non-hematological cause (n = 5; 10%); cause of death was not assessed in 2 cases. Regarding the use of donor lymphocytes infusion (DLI), 12 patients received DLI, with a median number of one infusion (range, 1-4). Eight patients received DLIs because of relapse, with a sustained response in six patients. When DLIs were infused for mixed chimerism (n = 5), an improvement of chimerism was noticed in three cases.
For all patients, median PFS and OS calculated from time of RICallo-SCT were 30.1 and 62 months, respectively (Figure 1a) . For surviving patients after d100, median PFS and OS from time of RIC-allo-SCT were 41.5 months and 71.5, respectively (Figure 1b) . TRM rates were 17, 29 and 32% at 6 months, 1 year and 3 years, respectively (Figure 1c ). Abbreviations: aGvHD = acute GvHD; cGvHD = chronic GvHD; NA = not asserted; OS = overall survival; Ric-allo-SCT = reduced-intensity conditioning allogeneic stem cell transplantation. *Limited to patients whose FU reached day 100.
RIC-allo-SCT in MCL after auto-SCT failure B Tessoulin et al
Statistical analyses of patient outcome
Results are presented in Tables 3 and 4 . No prognostic markers available before RIC-allo-SCT, except disease status prior to RICallo-SCT, reached statistical significance in univariate analysis for both PFS and OS. Median PFS for patients who achieved at least a PR was 34 months, compared with 4 months for patients with PD (P = 0.008; Figures 2a and b) . Median OS was 63 months for patients with PR/CR compared with 6 months for patients with PD (P = 0.0007). Interestingly, we found no difference for OS and PFS according to time between auto-SCT to RIC-allo-SCT, or number of lines of treatment prior to allo-SCT. The period of RIC-allo-SCT did not modify patient outcome. When grouping conditioning regimens into fludara-busulfan-ATG (n = 53), other combination without ATG (n = 43) and other with ATG (n = 10), no differences in terms of TRM (P = 0.8), PFS (P = 0.7) and OS (P = 0.5) were found. Patients with grade III/IV aGvHD had a shorter PFS and OS compared with patients with low-grade aGvHD or without aGvHD (4.3 vs 62 vs NR, P = 0.002; Figures 3a and b) . In univariate analysis, ATG was associated with a reduced risk of severe aGvHD (35% vs 65%, P = 0.03) but not with TRM (P = 0.66), PFS (P = 0.43) and OS (0.37) rates. Regarding cGvHD development, there was a better PFS in favor of patients (only patients who were alive after day +100 were included for this sub-group analysis, n = 96) who experienced limited cGvHD as compared with patients who did not experience cGvHD (NR vs 10 months, P = 0.002). We found no statistically significant difference in PFS in patients with extensive cGvHD compared with those without cGvHD (51 vs 10 months, P = 0.27). Limited cGvHD was associated with a trend of improved PFS when compared with patients with extensive cGvHD (NR vs 51 months, P = 0.06). However, improved PFS and limited cGvHD did not translate significantly (P = 0.008) into longer OS (Figure 4) .
When implementing multivariate analysis with factors associated (P o 0.2) with PFS and OS of patients surviving by day +100 (cGvHD and disease status at time of transplant), these two factors remained significantly associated with both PFS and OS. Namely, PD was associated with an increased risk of relapse or death of 2.7 (95% CI, 1.15-6.3, P = 0.02), whereas limited cGvHD was associated with a protective effect for relapse of 0.28 (95% CI, 0.1-0.7, P = 0.01). Extensive cGvHD did not modified PFS risk. Regarding OS, PD was associated with an increased risk of 3.6 (95% CI, 1.5-8.7, P = 0.005), whereas limited cGvHD remained a protective factor with an OR of 0.28 (95%, 0.1-0.81, P = 0.02); extensive cGvHD did not modify OS compared with patients without cGvHD.
TRM was not affected by disease status and rituximab exposure prior to RIC-allo-SCT, time from auto-SCT to RIC-allo-SCT, and age at graft (o 60 vs ⩾ 60 years). Development of a cGvHD was not associated with a trend for a higher TRM (P = 0.1). Development of grade III/IV aGvHD was associated with a much higher rate of TRM at 1 year (P = 0.0001) 65% (grade III-IV aGvHD) vs 20% (grade I-II aGvHD) vs 20% (no aGvHD). Abbreviations: ATG = anti-thymoglobulin; BEAM = BCNU, etoposide, aracytine, melphalan; BU = busulfan; Flu = fludarabine; TRM = treatmentrelated mortality.
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DISCUSSION
The present work is a national retrospective survey of a large (n = 106) population of MCL patients treated with auto-SCT, modern standard of care. We show that a long-term disease-free state after RIC-allo-SCT is achievable for MCL patients with chemosensitive disease at time of allo-SCT, regardless of number of treatment lines prior to RIC-allo-SCT. Thus, the immune action against MCL cells caused by donor graft can eradicate residual chemo-resistant MCL cells. However, our work shows an unexpected high-TRM rate and a continuous incidence of relapse over time without a true plateau phase. For patients with MCL who underwent RIC-allo-SCT, one major cause of death is TRM due to GVH. Herein, 54% of patients experienced aGvHD, including 19% of grade III/IV. Incidences of both aGvHD and extensive cGvHD were high in the setting of RICallo-SCT but similar to other studies on MCL where incidence of aGVH varied from 14 to 57%. 8, 9, 13 Only one monocentric study from the MD Anderson group reported a significantly lower incidence of aGvHD. 8 As reported by others, we also observed that limited cGVHD is associated with a positive impact on PFS, explained by the GV-MCL effect. 9, 14 A positive impact by the GV-MCL effect has been shown by Spanish and British studies that investigated alemtuzumab-containing conditioning regimen. 7, 15 Toxicity of GvHD is significantly reduced when an alemtuzumabcontaining conditioning regimen is used but this is countered by a higher incidence of relapse because of the alemtuzumab-induced T-cell depletion that abrogates the GVD-MCL effect. It is difficult to explain why MCL patients have a higher risk of GvHD compared with other patients with mature B-cell malignancies undergoing RIC-allo-SCT. 16 The nature of MCL disease frequently involves bone marrow and/or digestive tissue and could be part of the explanation. The use of auto-SCT in previous lines and the Abbreviations: aGvHD = acute GvHD; auto-SCT = autologous stem cell transplantation; cGvHD = chronic GvHD; CI = confidence interval; OR = odds ratio; OS = overall survival; PD = progressive disease; RIC-allo-SCT = reduced-intensity conditioning allogeneic stem cell transplantation; SD, stable disease. Regarding relapse, all studies except one 8 show a continuous risk of relapse over time after RIC-allo-SCT in MCL. The percentage of patients who relapsed within a year after RIC-allo-SCT is ranked between 20 and 50%, 7, 17 and late relapse is not a rare event. In our analysis, 13 patients (out of 49 patients who were alive after 2 years post RIC-allo-SCT) relapsed 42 years after RIC-allo-SCT, including one who relapsed 410 years post-allo. Similar observations have been reported. 9, 17 Considering the delay between median PFS and OS (30 months), more details are provided in the Supplementary Table 1 . Relapsing patients were treated with various therapies (chemotherapy, radiotherapy, immune-strategies) ensuring fairly long-term responses considering these advanced diseases relapsing after an intensive strategy. Interestingly, early and late relapses are two different issues. Early relapse is related to insufficient disease control at the time of RIC-allo-SCT due to chemo-resistance. Late relapse is due to minimal residual tumor cells (MRD) with long latency that escape to the GV-MCL. Recent evidence shows that rituximab maintenance after first-line treatment prolongs OS and/or PFS, 18, 19 suggesting that these residual MCL cells responsible for late relapse are sensitive to a constant therapeutic anti-MCL pressure. The European MCL networks demonstrated that MRD negativity was predictive of patient outcome. 20 A systematic or MRD-driven maintenance after RIC-allo-SCT could therefore be an interesting approach to eradicate residual MCL cells or to prevent clinical relapse. DLIs could also be a therapeutic for MCL patients with MRD positivity after RIC-allo-SCT, but with an increased risk of GvHD. Other options are also being discussed. New drugs like bortezomib, temsirolimus and lenalidomide used alone, or in combination, offer interesting options but likely will not cure patients. More interestingly, new molecules have recently demonstrated highanti-MCL efficacy. Ibrutinib is an oral BTK (Bruton's tyrosine kinase) inhibitor that produces unprecedented responses in MCL when used as a single agent in patients with relapsed refractory disease. 21 The overall response rate observed was approximately double compared with other single-agent drugs in this setting. New BTKs are currently under investigation. New classes of molecules like PI3-k inhibitors and BH-3 mimetics or new generations of antibodies will likely emerge in the near future. Thus, the present and future therapeutic arsenals against MCL are increasingly important, with future trials hopefully confirming curative therapeutics. Interesting options would be to associate RIC-allo-SCT with these new agents. New molecules could then be used as a bridge to obtain CR before RIC-allo-SCT, and/or include in the conditioning regimen, and/or use as maintenance after RICallo with a MRD-driven approach. Some may argue that a patient treated with a new molecule like Ibrutinib, who reaches CR and good quality of life, should not be exposed to RIC-allo-SCT toxicity. This argument makes sense given there is no evidence today that new drugs will provide long-term CR or cure patients. Knowledge about long-term toxicities of these new drugs is also unknown. A key factor to take into consideration is how one line of treatment affects the next in a particular disease like MCL, where many therapeutic options exist and where most patients progress slowly. Identification of prognostic biomarkers would be of great value to choose among new drugs, allo-SCT or a sequential approach using both. 22 In summary, our report shows that (i) RIC-allo-SCT rescue for chemo-sensitive relapse or refractory MCL patients who relapsed after auto-SCT provides long-term remission for some patients, (ii) TRM and relapse are the two primary concerns. There is an urgent need for less toxic MCL-adapted conditioning regimens and post-allo strategies. The value of RIC-allo-SCT for relapse or refractory previously auto-SCT patients needs to be further evaluated in the emergence of new active targeted therapies for MCL. 
